Literature DB >> 1379906

Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

D J Dodwell1, E S de Campos, J A Radford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1379906     DOI： 10.2165/00003495-199244010-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  30 in total

Review 1.  The use of chemotherapy in the treatment of Hodgkin's disease.

Authors:  D L Longo
Journal:  Semin Oncol       Date:  1990-12       Impact factor: 4.929

Review 2.  Chemotherapy for large cell lymphoma: a status update.

Authors:  P I Yi; M Coleman; L Saltz; L Norton; A A Topilow; K Adler; B Bernhardt
Journal:  Semin Oncol       Date:  1990-02       Impact factor: 4.929

3.  Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin.

Authors:  G N Pillai; F B Hagemeister; W S Velasquez; J A Sullivan; D A Johnston; J J Butler; C C Shullenberger
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

4.  The description of chemotherapy delivery: options and pitfalls.

Authors:  C M Coppin
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

5.  Biochemical, biological, pharmacologic, toxicologic, kinetic and clinical (subhuman and human) relationships.

Authors:  H E Skipper
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

6.  Twenty years of MOPP therapy for Hodgkin's disease.

Authors:  D L Longo; R C Young; M Wesley; S M Hubbard; P L Duffey; E S Jaffe; V T DeVita
Journal:  J Clin Oncol       Date:  1986-09       Impact factor: 44.544

7.  Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.

Authors:  A Santoro; V Bonfante; G Bonadonna
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

8.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

Authors:  P Carde; F R MacKintosh; S A Rosenberg
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

9.  Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.

Authors:  S Jagannath; J O Armitage; K A Dicke; S L Tucker; W S Velasquez; K Smith; W P Vaughan; A Kessinger; L J Horwitz; F B Hagemeister
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

Review 10.  Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.

Authors:  A Kessinger; A Nademanee; S J Forman; J O Armitage
Journal:  Hematol Oncol Clin North Am       Date:  1990-06       Impact factor: 3.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.